Multiplexed Assay Kit for SLE Biomarker Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for systemic lupus erythematosus (SLE) are non-specific and have high false positive rates, making it challenging to accurately detect the disease before clinical symptoms appear and to evaluate the efficacy of treatment regimens.
Innovation Solution
A method involving the measurement of biomarkers such as MVP, RPS13, and combinations thereof, including SSB and TRIM21, to assess the presence of SLE and the effectiveness of treatment regimens, using a multiplexed assay kit to evaluate the levels of these biomarkers in patient samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-nuclear antibodies (ANAs) are used for SLE diagnosis, then the diagnostic coverage is improved, but the specificity deteriorates with high false positive rates
Solution Approach 1:
The patent segments the single ANA test into multiple specific autoantibody tests targeting different antigens (MVP, RPS13, SSB, TRIM21, Sm, RNP, dsDNA). By dividing the broad ANA screening into specific antibody measurements, the system maintains high diagnostic coverage while improving specificity through targeted detection of disease-associated autoantibody patterns.
Solution Approach 2:
The patent changes the diagnostic parameter from a single broad ANA measurement to a profile of multiple specific autoantibody levels. By measuring the presence and levels of different autoantibodies against specific antigens, the system transforms the diagnostic approach to achieve both high sensitivity (detecting all SLE cases) and high specificity (distinguishing SLE from other conditions).
2Measurement precision
If multiple biomarkers are measured simultaneously, then the diagnostic accuracy is improved, but the assay complexity increases
Solution Approach 1:
The patent merges multiple individual autoantibody detection assays into a single multiplexed assay platform. By combining the detection of multiple autoantibodies (anti-MVP, anti-RPS13, anti-SSB, anti-TRIM21, anti-Sm, anti-RNP, anti-dsDNA) into one test, the system achieves high diagnostic accuracy while reducing the number of separate assays needed, thereby managing complexity through integration rather than multiplication of separate tests.
Solution Approach 2:
The patent creates a universal assay platform that can detect multiple different autoantibodies using a common methodology and detection system. This multi-functional approach allows the same assay infrastructure to measure various autoantibody types simultaneously, improving diagnostic accuracy without proportionally increasing operational complexity.
3Loss of time
If autoantibodies are detected prior to clinical symptoms, then the early detection capability is improved, but the risk of false positives increases
Solution Approach 1:
The patent enables preliminary detection of autoantibodies before clinical symptoms appear, allowing early identification of individuals at risk for SLE. By measuring autoantibody levels in asymptomatic individuals, the system detects the disease process at an early stage when autoantibodies are present but clinical manifestations have not yet developed.
Solution Approach 2:
The patent uses the pattern and combination of multiple autoantibodies as feedback to distinguish true positive cases from false positives. By analyzing the presence, absence, and relative levels of different autoantibodies together rather than in isolation, the system can identify characteristic patterns associated with early SLE while filtering out isolated autoantibodies that may represent false positives or other conditions.
Data Source
AI summary
The present disclosure relates to multiplexed assay formats configured to measure the level of a plurality of biomarkers that include a protein array for detecting autoreactive antibody levels against autoantigens.